BioWorld

Aug. 14, 2008

Talecris Opts for $3.1B Merger Instead of IPO

Talecris Biotherapeutics Inc. said it is being acquired by Australian firm CSL Ltd. in a $3.1 billion cash merger that would form one of the largest plasma-derived therapeutics firms worldwide. (BioWorld Today) Read More

Genentech Rejects Roche Offer, as Biotech's Shares Near $100

Immune Suppressant Can Stimulate Immune System

Anthera Raises $19M to Boost Work in Anti-inflammatories

Clinic Roundup

Other News To Note

Earnings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 14, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...